Skip to main content
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 2011 Jul 15;89(1):56–66. doi: 10.1016/j.ajhg.2011.05.027

Functional Mutation of SMAC/DIABLO, Encoding a Mitochondrial Proapoptotic Protein, Causes Human Progressive Hearing Loss DFNA64

Jing Cheng 1,10, Yuhua Zhu 1,10, Sudan He 2,3, Yanping Lu 4, Jing Chen 1, Bing Han 1, Marco Petrillo 5, Kazimierz O Wrzeszczynski 6, Shiming Yang 1, Pu Dai 1, Suoqiang Zhai 1, Dongyi Han 1, Michael Q Zhang 6, Wei Li 7, Xuezhong Liu 8, Huawei Li 9, Zheng-Yi Chen 5, Huijun Yuan 1,
PMCID: PMC3135809  PMID: 21722859

Abstract

SMAC/DIABLO is a mitochondrial proapoptotic protein that is released from mitochondria during apoptosis and counters the inhibitory activities of inhibitor of apoptosis proteins, IAPs. By linkage analysis and candidate screening, we identified a heterozygous SMAC/DIABLO mutation, c.377C>T (p.Ser126Leu, refers to p.Ser71Leu in the mature protein) in a six-generation Chinese kindred characterized by dominant progressive nonsyndromic hearing loss, designated as DFNA64. SMAC/DIABLO is highly expressed in human embryonic ears and is enriched in the developing mouse inner-ear hair cells, suggesting it has a role in the development and homeostasis of hair cells. We used a functional study to demonstrate that the SMAC/DIABLOS71L mutant, while retaining the proapoptotic function, triggers significant degradation of both wild-type and mutant SMAC/DIABLO and renders host mitochondria susceptible to calcium-induced loss of the membrane potential. Our work identifies DFNA64 as the human genetic disorder associated with SMAC/DIABLO malfunction and suggests that mutant SMAC/DIABLOS71L might cause mitochondrial dysfunction.

Introduction

Hearing loss affects an estimated 28 million Americans, 27.8 million Chinese, and 22.5 million Europeans.1–3 It was estimated that several-hundred genes could be associated with this sensory deficit in humans. This high genetic heterogeneity could reflect the anatomical and functional complexity of the inner ear. In the past two decades, extensive research efforts on the genetics of hearing loss led to the mapping of 143 loci and the identification of 62 genes responsible for nonsyndromic hearing loss (Hereditary Hearing Loss homepage; see Web Resources). The identification of genes for autosomal-dominant nonsyndromic hearing loss (DFNA) will be important for understanding age-related hearing impairment, the most prominent form of hearing loss. Gene mutations associated with late-onset progressive disorders are most likely to result in less drastic changes in protein structure and function. The progressive nature of these diseases could then be explained by a gradual increase in the ratio of damaged to normal proteins or changes in protein level.4 The genes involved in human nonsyndromic hearing loss encode proteins with a wide spectrum of biological structures and functions, including transcriptional regulation, K+ recycling, the cytoskeleton, cell-cell junctions, membrane transport, the extracellular matrix, and other structural components.5,6

Loss of hair cells, the auditory sensory cells, by apoptosis is a major cause of hearing loss in mammals.7–9 A recent study showed that Bak, a proapoptotic protein, is involved in age-related hearing loss in mice.10 However, none of the 62 human genes involved in nonsyndromic hearing loss is known to have a proapoptotic function. Only TJP2 (MIM 607709) was recently reported to participate in apoptosis pathways by altering expression of apoptosis genes through genomic duplication and overexpression in DFNA51 (MIM 613558).11 In 2000, Du et al. identified SMAC (second mitochondria-derived activator of caspase, MIM 605219, accession number AAF87716.1), a proapoptotic mitochondrial protein that promotes caspase activation by relieving IAP inhibition.12 Verhagen et al. identified the murine homolog of SMAC and named it DIABLO (direct inhibitor of apoptosis protein binding protein with a low pI).13 SMAC/DIABLO (hereafter referred to as DIABLO, which has been approved by the HUGO Gene Nomenclature Committee) is synthesized as a 239 amino acid precursor molecule. The amino-terminal 55 residues serve as the mitochondria-targeting sequence, which is removed after the Smac protein is imported into mitochondria intermembrane space. Chai et al. determined the crystal structure of DIABLO, which revealed that DIABLO must form a homodimer to interact with IAPs. A particular N-terminal motif, consisting of four amino acids, Ala-Val-Pro-Ile, is responsible for the interaction with IAPs. DIABLO interacts with the BIR2 and BIR3 domains of XIAP, allowing the release of caspase-3 and caspase-9, respectively.14

Given its central role in regulating apoptosis, it is expected that DIABLO dysfunction might underlie the pathogenesis of some human diseases. However, no DIABLO mutation that is associated with any human genetic disorders has previously been identified. In this paper, we report the identification of a DIABLO missense mutation that underlies autosomal-dominant hearing loss, designated as DFNA64, in a six-generation Chinese kindred. We report a functional study to illustrate that the identified mutation causes degradation of mutant and wild-type DIABLO; this degradation is likely to lead to mitochondrial dysfunction and contributes to DFNA64.

Material and Methods

Clinical Evaluations

The family HN-W078 was ascertained from the Henan province of Mainland China. All the procedures were approved by the Ethics Reviewing Committee of the Chinese PLA General Hospital and were carried out only after written informed consent was obtained from each individual and/or parents of the children. The medical history was obtained by use of a questionnaire regarding the following aspects: subjective degree of hearing loss, age at onset, evolution, symmetry of the hearing impairment, hearing aids, presence of tinnitus and vertigo, medication, noise exposure, pathologic changes in the ear, and other relevant clinical manifestations. Otoscopy, physical examination, and pure-tone audiometry (at frequencies from 250 to 8000 Hz) were performed. Immittance testing was applied so that middle-ear functions could be evaluated.

Linkage Analysis

Blood samples (3 ml) were drawn from 33 participants so that genomic DNA could be extracted with the Genomic DNA isolation kit (QIAGEN). A genome-wide scan was performed for a selected 18 subjects via Affymetrix Genome-Wide Human SNP Array 5.0 containing 57,244 SNPs. Multipoint parametric linkage analysis was performed with Merlin v. 1.0 so that parametric LOD scores could be calculated. Penetrance values used for the dominant model were 0.01, 0.90, and 0.90 for the wild-type homozygote, mutant heterozygote, and mutant homozygote, respectively. We assumed a disease allele prevalence frequency of 0.0001 and a phenocopy rate of 1%. Fine mapping was performed with ten microsatellite markers selected from Marshfield chromosome 12 map. The alleles were assigned with Genescan and Genotyper Software (Applied Biosystems, USA). Linkage analysis was performed with the LINKAGE 5.1 software package. The two-point LOD score between the deafness locus and each marker was calculated under a fully penetrant autosomal-dominant mode of inheritance, and the disease allele frequency was set to 0.0001. The meiotic recombination frequencies were considered to be equal for males and females.

Mutation Analysis

Direct sequencing was used for mutation screening. Primers were designed to amplify all exons and flanking intronic splicing sites of genes from genome DNA. Sequences of these primers are given in Table S1, available online. The accession numbers and versions of candidate genes are listed in Table S2.

Quantitative RT-PCR

Expression of DIABLO transcript in different human embryonic tissues at week 17 of pregnancy was evaluated by real-time quantitative RT-PCR. All the procedures were approved by the Ethics Reviewing Committee of the Chinese PLA General Hospital. Total RNA was purified with the Trizol method (Invitrogen) and treated with DNase I (QIAGEN). Total RNA (1 μg) was reverse transcribed with the SuperScript III First-Strand Kit (Invitrogen). Amplimer levels were quantified continuously with the SYBR Green system (Applied Biosystems) for analysis of transcript expression of tissues, and the Taq-Man MGB probe system (Applied Biosystems) was applied for the analysis of the transcription of wild-type and mutant DIABLO in HeLa cells. Gene expression levels were calculated with the 2(−ΔΔCT) method. Target-gene expression was normalized to β-actin expression.

Cell-Viability Assay

Cell-survival analysis was performed with the Cell Titer-Glo Luminescent Cell-Viability Assay kit (Promega) according to manufacturer instruction with minor modification. In brief, 20 μl of Cell Titer-glo reagent was added to the cell culture medium. Luminescent reading was carried on Tecan SpectraFluor Plus reader (Tecan).

Site-Directed Mutagenesis and Recombinant-Protein Preparation

We generated point mutations by using the QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene).

Immunoprecipitation

Cell lysates were incubated with M2 FLAG agarose beads (Sigma) overnight at 4°C. Beads were washed with lysis buffer containing an additional 300 mM NaCl. The immunoprecipitants were eluted off the beads with low pH elution buffer (Pierce) for 5 min at room temperature. Acid elution was neutralized by the addition of a 1/20 volume of 1 M Tris-HCl (pH 9.4).

Immunolot Analysis

Antibodies were used according to the manufacturer's suggestion. Immunoblot analysis was performed with a horseradish-peroxidase-conjugated goat anti-rabbit immunoglobulin G and enhanced chemiluminescence (ECL) immunoblotting detection reagents (Sigma).

Immunohistochemistry

Mouse inner-ear tissues from timed pregnancy were collected via a previously described procedure.15 The use of animals and the procedures involving tissue preparation were approved by the Institutional Animal Care and Use Committee of the Massachusetts Eye and Ear Infirmary. Standard procedures were employed for staining cryosectioned mouse cochlear slides and HeLa cells with the antibodies against the following antigens: DIABLO antibody [Y12] (1:200 for HeLa cells, 1:1000 for cochlear slides, Abcam, ab32023), MitoTracker Mitochondrion-Selective Probes (1:5000, Molecular Probe), and DAPI (1×, Molecular Probe).

Smac-XIAP Binding Assay

Pellet cells were centrifuged from culture media and were washed with phosphate-buffered saline (PBS) and solubilized in 200 μl ice-cold extraction buffer (50 mM HEPES [pH 7.5], 10 mM KCl, 5 mM EGTA, 1 mM MgCl2, 0.2% Chaps, and 0.2 mM DTT) at a density of 2 × 108 cells/ml. The cell pellet was snap frozen in liquid nitrogen and stored at −80°C. Thawed cell were extracted and centrifuged at 14,000 × g for 15 min at 4°C. Then, 10 μl of cell extract was added to tubes containing bovine heart cytochrome c (Sigma, 5 μl of a 1 mg/ml stock), dATP (Sigma, catalog # D6500, 5 μl of a 5.0 mM stock adjusted to pH 7.5 with KOH), and 5 μl of recombinant XIAP protein with or without 5 μl recombinant wild-type and mutant DIABLO. The samples were incubated in a 37°C water bath for 60 min. The cleaved fractions were detected by immunoblot with caspase-3 antibody (Cell signaling, 9662).

Knockdown of Smac by siRNA Transfection

MISSION esiRNAs (Sigma) are endoribonuclease-prepared siRNA pools comprised of a heterogeneous mixture of siRNAs that all target the same mRNA sequence. MISSION siRNA was transfected according to the manufacturer's instructions.

Live-Cell Imaging of Mitochondrial Membrane Permeability

HeLa cells were plated in cultured media (DMEM from Hyclone, 10% FBS, and 1% P/S). Fresh media containing 25 nM TMRM (T668, Invitrogen) and 100 nM mitoTracker Green (M7514, Invitrogen) was added, and incubation followed for 25 min at 37°C under protection from light. Warm media containing 200 μM CaCl2 and 20 μM A23187 (C7522, Sigma) were added. Images were acquired at every 10 min thereafter with a ZEISS 40×/1.42 confocal microscope. Each image was comprised of eight z stacks in which each section was 1 μM in depth.

Results

Family and Clinical Evaluations

The pedigree of family HN-W078, which spans six generations and comprises 127 members, is consistent with an autosomal-dominant inheritance pattern (Figure 1). Thirty-three family members, including 18 affected members and 15 normal individuals, participated in this study. Responses to questionnaires indicated that the age of onset of hearing impairment in this family varied from 12 to 30 years (the average age of onset was 22 years). In 18 affected subjects, hearing impairment was symmetric. The severity of hearing impairment varied from severe to moderate to mild hearing according to the subjects' audiograms. The severity of hearing impairment appears to be correlated with the individual's age (Table 1). Overall, the audiograms of affected members have a flat contour (Figure 1). High-frequency tinnitus was reported in 73% of affected members at the onset of hearing loss. Audiologic evaluation of the family members demonstrated normal immittance testing and bone conduction values that equal the air conduction measurements, suggesting a sensorineural hearing impairment. Comprehensive family medical histories and clinical examination of these individuals showed no other clinical abnormalities, including diabetes, cardiovascular diseases, visual problems, or neurological disorders. Inner-ear malformations were ruled out by computer tomography, which was normal in the proband of this family.

Figure 1.

Figure 1

Pedigree of Chinese Family HN-W078 with Dominant Progressive Hearing Loss and a Combined Audiogram of Affected Subjects

Affected subjects are denoted in black. The proband is indicated by an arrow. On the basis of the audiograms of the affected subjects, the severity of hearing impairment appears to be correlated with the individual's age.

Table 1.

Summary of Clinical Data for Some of the Affected Individuals of Family HN-W078

Patient Gender Age (Years)
Use of Aminoglycoside Hearing Test PTA(dB HL)
Audiogram Shape Level of Hearing Impairment Vertigo Tinnitus
At Testing At Onset Left Ear Right Ear
II:7 female 76 24 no 80 88 flat severe no yes
III:10 male 60 22 no 79 80 flat severe no yes
III:13 male 59 26 no 110 76 flat severe no yes
III:15 female 53 20 no 66 66 flat moderate no yes
III:19 female 52 30 no 60 62 flat moderate no no
IV:3 male 52 24 no 61 68 flat moderate no yes
IV:6 male 49 24 no 63 64 flat moderate no yes
IV:8 male 40 23 no 71 71 flat severe no no
IV:10 male 55 20 no 76 78 flat severe no yes
IV:24 male 30 15 no 70 70 flat severe no yes
IV:26 female 26 20 no 58 55 sloping moderate no yes
IV:31 male 18 12 no 48 48 flat moderate no yes
IV:33 male 33 26 no 60 69 flat moderate no yes
IV:35 female 31 20 no 58 59 flat moderate no yes
V:13 male 27 23 no 53 54 sloping moderate no no
V:27 female 23 16 no 41 44 flat moderate no no

The degree of hearing loss was defined according to pure-tone averages (PTAs), which were based on the frequencies 500, 1,000, and 2,000 Hz.

Mapping of DFNA64 Locus

Multipoint genome-wide linkage analysis yielded a positive region with single-nucleotide polymorphism (SNP) markers on chromosome 12q24.31–12q24.32 (chr12:121,924,854 −128,895,742) between markers rs7955747 and rs10773539 and a maximum logarithm of the odds (LOD) score of 5.66 (Figure 2A). Fine mapping employing extensive microsatellite markers placed a genetic interval between markers D12S86 and D12S1612 (Figure 2B; see also Figure S1). The combination of these two methods allowed us to narrow down the critical interval harboring a candidate locus between the markers rs7955747 and D12S1612, which did not overlap with the flanking DFNA25 (MIM 605583) or DFNA41 (MIM 608224) locus (Figure 2C).16,17 Thus, we identified a dominant deafness locus, designated as DFNA64 by the Human Genome Organization (HUGO) Gene Nomenclature Committee.

Figure 2.

Figure 2

Mapping Interval and Mutation Analysis of the Chinese Family HN-W078

(A) Genome-wide linkage analysis with SNP markers defined an interval between markers rs7955747 and rs10773539 and gave a maximum HLOD score of 5.66.

(B) Fine mapping of the candidate region with microsatellite markers defined an interval between markers D12S86 and D12S1612 and gave a maximum LOD score of 5.35.

(C) Idiogram of the DFNA64 locus on chromosome 12 with flanking markers and candidate genes. The loci of DFNA25, DFNA41, and DFNA48 are also indicated.

(D) The genomic structure of different DIABLO transcripts. The position of the DFNA64 mutation in exon 5 is shown. DIABLO has four different transcripts, but only two of them encode proteins. NM_019887.4 is the longest transcript and encodes NP_063940.1. NM_138929.3 encodes a shorter isoform, NP_620307. Both transcripts harbor exon 5, where the c. 377C>T mutation is located.

(E) DNA sequence chromatograms showing a heterozygous c.377C>T mutation in DIABLO in DFNA64 individuals are compared to those of wild-type controls.

(F) Conservation analysis showing that Ser126 in DIABLO is conserved across human, rat, mouse, bovine, ornithorhynchus, chicken, and Xenopus lineages.

Identification of a Mutation in the DFNA64 Family

The mapped DFNA64 locus spans a physical distance of 3.09 Mb. More than 61 RefSeq genes have been identified in this interval. Sequence analysis of six candidate genes selected from the Morton Cochlear EST Database,18 PSMD9 (MIM 603146, 26S proteasome subunit), CDK2AP1 (MIM 602198, functions in the oncogenic process), DIABLO (MIM 605219, functions in the mitochondrial apoptotic pathway), KDM2B (MIM 609078, putative tumor suppressor), ZCCHC8 (gene ID 55596, GSK-3 substrate, functions in RNA metabolism), and SBNO1 (gene ID 55206, functions in the Notch signaling pathway), led to the identification of a heterozygous C-to-T transition at position 377 in exon 5 (NM_019887.4: c.377 C>T, Figures 2D and 2E). This transition resulted in a p.Ser126Leu (p.Ser71Leu in mature protein) substitution in DIABLO. The Ser residue at position 126 in DIABLO is conserved across human, rat, mouse, bovine, ornithorhynchus, chicken, and Xenopus lineages (Figure 2F). EcoR I restriction analysis demonstrated that the c.377 C>T mutation completely cosegregated with hearing loss in family HN-W078 and was absent in 1000 unrelated Chinese control chromosomes. The penetrance of hearing loss in this family is 100% on the basis of the data from investigated individuals. All variants identified in six candidate genes in this family are listed in Table S2. We have screened 223 Chinese families or sporadic subjects with late-onset hearing loss (<40 years). We did not find any DIABLO mutation in those samples.

DIABLO Is Highly Expressed in the Human and Mouse Inner Ear

To investigate the role of DIABLO malfunction in DFNA64, we first examined the expression of DIABLO in different human embryonic tissues by using real-time quantitative RT-PCR. DIABLO mRNA was detected broadly; the highest expression was in the testis, adrenal gland, and ears, there was moderate expression in the brain, eyes, liver, kidney, lung, and spinal cord, and there was low expression in the spleen (Figure 3A). We next studied the production of Diablo in the developing mouse inner ear with an anti-DIABLO antibody. Diablo was widely expressed at a low level in the developing mouse cochlea (Figure 3C). However, Diablo was significantly upregulated in hair cells from E18.5 to P0 and was subsequently downregulated. A secondary antibody control did not produce any discernable staining pattern (data not shown). The extended distribution of Diablo at different stages of development in the mouse inner ear and the particular enrichment in hair cells suggested that Diablo functions in the development and homeostasis of the inner ear and in hair cells in particular.

Figure 3.

Figure 3

Expression Profiling of DIABLO in the Developing Human and Mouse Inner Ear

(A) Expression of DIABLO transcript in different human embryonic tissues at week 17 of pregnancy was evaluated by real-time quantitative RT-PCR. Data are means ± SD of three independent experiments.

(B) Schematic representation of the Corti's organ in the inner ear. The sensory epithelium of the cochlea consists of inner and outer hair cells. Supporting cells of the Corti's organ include Hensen's, Claudius's, Deiter's, and Boettcher's cells.

(C) Production of DIABLO in the developing mouse cochlea. (I) Cytoplasmic distribution of DIABLO was weakly detected ubiquitously in developing cochlea, including the nascent inner hair cell (IHC) at the base, at E15.5. (II) By E18.5, DIABLO production was significantly elevated in both inner and outer hair cells (IHCs and OHCs), in particular in the cytoplasm above the nuclei. DIABLO was also readily detected in other cell types, including the greater epithelial ridge (GER). (III) DIABLO production was persistently higher in cochlear hair cells at P0 than in surrounding cells. More than three OHCs were present in the image because of the section angle. (IV) By P6, DIABLO was downregulated to a level that was indistinguishable from that of the GER. Myo7a: myosin VIIa that labels hair cells. Magnification: 40×.

Mutant DIABLO Has Similar Proapoptotic Activity to Wild-Type Protein

We carried out bioinformatics analysis to predict the likely functional impact of the DIABLOS71L mutant on the basis of the crystal structure of the wild-type DIABLO (PDB ID: 1FEW). It was indicated that Ser 71 is located at a distance from the XIAP-binding site and on the opposite end of the dimer interface (Figure 4A). Serine 71 might form a hydrogen bond with neighboring Asp 75 and thus stabilize the H1-H2 loop. Disruption of this hydrogen bond could cause protein misfolding or structural damage (data not shown). To test whether the DIABLOS71L mutation would disrupt the DIABLO dimer formation and DIABLO-XIAP binding activity, we expressed human wild-type (DIABLOWT) and mutant DIABLO (DIABLOS71L) in an E. coli system. The purified recombinant DIABLOS71L and DIABLOWT showed similar profiles on Sephedex 200 columns and on native polyacrylamide gel electrophoresis (PAGE), indicating that DIABLOS71L is able to form a dimer (Figure 4B). We then investigated DIABLO-XIAP binding activity by assessing caspase 3 activation in an in vitro system. As shown in Figure 4C, procaspase 3 was activated and cleaved into two fragments of P20 and P12 in activated HeLa cell extracts (lane 2); this activity was blocked by the addition of purified recombinant XIAP (lanes 3 and 4). The inhibition of procaspase 3 activation by XIAP was removed by further incubation with DIABLOWT (lanes 5 and 6) or DIABLOS71L (lanes 9 and 10) in a dose-dependent manner. These observations demonstrated that DIABLOS71L does not jeopardize DIABLO-XIAP binding activity. We further investigated the effect of DIABLOS71L mutation on apoptosis in cultured cells. As shown in Figure 4D, HeLa cells overexpressing DIABLOWT or DIABLOS71L showed no significant difference of cell viability when treated with several proapoptotic agents, including etoposide, Actinomycin D, and cisplastin, indicating that DIABLOS71L does not give rise to an increased apoptotic activity under these conditions.

Figure 4.

Figure 4

Effects of the DIABLOS71L Mutant on Dimer Formation and DIABLO-XIAP Binding

(A) Structure analysis of the wild-type DIABLO (PDB ID: 1FEW) using PyMol program indicates Ser 71 in mature protein is located at the end of the arch-shaped H1 helix. Binding XIAP is in yellow. The dimer interface is indicated by an arrow.

(B) The purified recombinant DIABLOS71L and DIABLOWT showed the same characters on Sephedex-200 columns and on native polyacrylamide gel electrophoresis (PAGE), indicating that DIABLOS71L is able to form a dimer. WT: wild-type, MT: DIABLOS71L mutant.

(C) DIABLO-XIAP binding activity assay. Procaspase 3 was activated and cleaved into two fragments of P20 and P12 when ctivated HeLa cell extracts (lane 2) were added; this activation and cleavage were blocked by the addition of recombinant XIAP (lanes 3 and 4). The inhibition of procaspase 3 activation by XIAP was removed by the addition of DIABLOWT (lanes 5 and 6) or DIABLOS71L (lanes 9 and 10). Neither 1 nor 10 ng DIABLOWT and DIABLOS71L was enough to antagonize the XIAP effect (lanes 7,8,11, and 12).

(D) Cell-viability assay. In HeLa cells overexpressing DIABLOWT or DIABLOS71L, no difference in cell death was observed after it was triggered by etoposide, Actinomycin D, or cisplastin. Data are represented as mean ± standard deviation of three independent experiments.

Ectopically Expressed DIABLOS71L Triggered Degradation of the Mutant and Wild-Type DIABLO in a Heterodimeration-Dependent Way in HeLa Cells

To further investigate the effect of DIABLOS71L, we tagged DIABLOWT and DIABLOS71L with FLAG and determined the expression of DIABLO fusion protein in HeLa cells. Similar levels of DIABLOWT and DIABLOS71L mRNA were observed by quantitative real-time RT-PCR analysis (data not shown). Surprisingly, when HeLa cells were transfected with the same amount of DIABLOWT or DIABLOS71L plasmids, the protein level of DIABLOS71L was much lower than that of the DIABLOWT transfected cells. Concurrently with the decreased in DIABLOS71L, the endogenous DIABLO showed a remarkable reduction in HeLa cells transfected with DIABLOS71L as opposed to DIABLOWT. Increasing expression of DIABLOS71L enhanced the degradation of wild-type DIABLO (Figure 5A). These observations were further confirmed by immunohistochemistry (Figure 5B). To determine whether the degradation was specifically induced by the DIABLOS71L mutant, we generated DIABLON70I and DIABLOE72L constructs and expressed them in parallel with DIABLOS71L in HeLa cells. In contrast to what we observed with the DIABLOS71L mutant, we did not observe the degradation of DIABLON70I, DIABLOE72L mutants, or endogenous DIABLO in the transfected cells (Figure 5C).

Figure 5.

Figure 5

Expression and Degradation of the DIABLOS71L Mutant in HeLa Cells

(A) Immunoblot analysis showed that DIABLOS71L and endogenous DIABLO decreased in a dose-dependent manner in the HeLa cells transfected with DIABLOS71L. Patterns of wild-type and mutant DIABLO did not change.

(B) Immunostaining shows a remarkable reduction of DIABLO in HeLa cells transfected with DIABLOS71L.

(C) DIABLOS71L, DIABLON70I, and DIABLOE72L mutants and DIABLOWT were expressed in parallel in HeLa cells. The reduction of mutant and endogenous DIABLO was observed only in DIABLOS71L-transfected HeLa cells.

(D) DIABLOS71L, DIABLOS71L+V26D, and DIABLOS71L+F33D mutants and DIABLOWT were expressed in HeLa cells. Similar levels of endogenous DIABLO were observed in cells transfected with DIABLOS71L+V26D, DIABLOS71L+F33D, and DIABLOWT, whereas endogenous DIABLO was decreased only in cells transfected with DIABLOS71L. DIABLOS71L, DIABLOS71L+V26D, and DIABLOS71L+F33D mutants were decreased in cell lysates (input, second, third, and forth lanes). Heterodimerization of DIABLOS71L with endogenous DIABLO was indicated by the clear band of endogenous DIABLO in elutions from DIABLOS71L-FLAG-agarose beads (elution, second lane). There was no detectable endogenous DIABLO pulled down from cells transfected with DIABLOS71L+V26D and DIABLOS71L+F33D (elution, third and forth lanes). XIAP was detected in both inputs, and elutions confirmed that DIABLOS71L, DIABLOS71L+V26D, and DIABLOS71L+F33D mutants bound to XIAP normally.

To test whether the degradation of endogenous DIABLO depends on the heterodimer formation of DIABLOS71L-endogenous DIABLO, we generated two constructs with the double mutations DIABLOS71L+V26D and DIABLOS71L+F33D, which have a defect in dimerization, as described previously.14 As shown in Figure 5D, DIABLOS71L as well as DIABLOWT formed dimers with endogenous DIABLO, and two monomeric DIABLO mutants (DIABLOS71L+V26D and DIABLOS71L+F33D) were unable to interact with endogenous DIABLO. Consistently, only DIABLOS71L and not DIABLOS71L+V26D or DIABLOS71L+F33D induced the degradation of endogenous DIABLO. These observations demonstrated that the expression of DIABLOS71L in the transfected HeLa cells leads to degradation of both the mutant and endogenous DIABLO through heterodimerization between them.

DIABLOS71L Renders Host Mitochondria Susceptible to Calcium-Induced Loss of Membrane Potential

Active degradation of DIABLOS71L indicates that the mutated protein might trigger mitochondrial stress. Mitochondrial membrane potential (Δψ) is a sensitive marker of mitochondrial function, and its reduction has been associated with mitochondrial dysfunction.19 To assess changes of ΔΨ in situ, we used tetramethylrhodamine methyl ester (TMRM), a monovalent cationic fluorescent dye widely used for measuring ΔΨ.20,21 In HeLa cells expressing DIABLOS71L, ΔΨ rapidly collapsed in response to calcium-induced mitochondria stress, whereas the integrity of mitochondrial structure was preserved, as shown by mitoTracker green staining (Figure 6B). Upon exposure to the same stimuli, cells expressing DIABLOWT exhibited intact Δψ (Figure 6A). We further investigated whether the increased sensitivity to mitochondrial stress was due to the expression of DIABLOS71L or to the loss of endogenous DIABLO. As shown in Figure 6C, expression of DIABLOS71L+V26D caused cells to lose Δψ, which was similar to what occurred in the DIABLOS71-transfected cells, whereas a significant decrease in the endogenous DIABLO by RNA interference (Figure S2) had no effect on Δψ (Figure 6D). These results strongly suggest that the impairment of mitochondrial membrane potential in the HeLa cells transfected with DIABLOS71L is specifically caused by the existence of DIABLOS71L, leading to the activation of a degradation machinery for constant clearance of aberrant proteins.

Figure 6.

Figure 6

Mitochondrial Membrane-Potential Assay

In HeLa cells transfected with DIABLOWT, DIABLOS71L, DIABLOS71L+V26D, and siRNA, mitochondrial membrane potential was monitored by the loss of tetramethylrhodamine methyl ester (TMRM) fluorescence after exposure to the calcium ionophore A23187.

(A and C) Mitochondrial membrane potential was preserved for at least 45 min after exposure to A23187 in DIABLOWT and siRNA transfection.

(B and D) In HeLa cells expressing DIABLOS71L or DIABLOS71L+V26D, a loss of mitochondrial membrane potential was observed 15–45 min after exposure to A23187. The integrity of mitochondrial structure was shown by immunostaining with mitoTracker green. Experiments were replicated three times with similar results.

Discussion

In the present study, a heterozygous missense mutation, c.377C>T, that is genetically linked to progressive, non-syndromic, sensorineural hearing loss in an extended Chinese DFNA64 family was identified in DIABLO. Because of the critical role of DIABLO in the apoptosis pathway, it was tempting to speculate that the pathological mechanism of DFNA64 might be associated with a gain of function in apoptosis in the inner ear. The possible gain of function of apoptosis could be mediated by the following mechanisms: (1) the DIABLOS71L mutant enhances the binding of XIAP-DIABLO; (2) the normal degradation of DIABLO is disrupted by the mutation, increasing the protein level of DIABLOS71L; or (3) the DIABLOS71L mutant enhances IAP auto-ubiquitination, increasing the degradation of IAPs. To test these hypotheses, we overexpressed both wild-type and mutant DIABLO in HeLa cells and used a cell-viability assay to compare their effects on apoptosis. We did not detect discernable differences in cell death induced by mutant or wild-type DIABLO. This is consistent with the prediction by molecular modeling that the p.Ser71Leu mutation is located at the end of the arch-shaped H1 helix, far away from the binding site of DIABLO-IAPs and the dimer interface, and thus might not impact the apoptotic function of DIABLO significantly.

An alternative hypothesis is that DFNA64 might be caused by an accumulation of DIABLOS71L protein that forms aggregates in hair cells. Such a mechanism has been described in neurodegenerative disorders, including Alzheimer, Huntington, and Parkinson diseases.22 However, overexpression of the DIABLOS71L mutant in HeLa cells did not lead to an increased level of aberrant DIABLO by in immunoblot analysis. In contrast, the protein level of DIABLOS71L decreased with the time of expression. Moreover, the endogenous wild-type DIABLO was degraded in the DIABLOS71L-expressing HeLa cells, and the degradation of DIABLOWT is dependent on DIABLOS71L-DIABLOWT dimerization. Although the mechanism underlying degradation is yet to be determined, these results demonstrate that the DIABLOS71L mutant exhibits a specific deleterious effect that can be recognized and cleared by host cells, and such an effect extends to native wild-type DIABLO as a result of dimerization with the mutant protein, leading to severe reduction of the overall DIABLO level.

By quantitative RT-PCR and immunohistochemistry, we have shown that DIABLO was highly expressed in the human embryonic inner ear and that the protein level was elevated in the developing mouse hair cells; these results are consistent with the potential function of DIABLO in mammalian inner-ear development and maintenance. The inner ear is a delicate organ with a limited number of postmitotic hair cells, whose differentiation and maturation state has to be precisely controlled, both for their survival and normal function. This is demonstrated by a disproportionally large number of hair cell genes in which mutations cause hair cell developmental defects, malfunction, or cell death, leading to hearing loss.

Mitochondria assume central functions, including ATP production, calcium homeostasis, reactive oxygen species generation, and apoptotic signaling, in cells. Inner-ear hair cells and neurons are particularly dependent upon proper mitochondrial function to support high-energy demand and cell maintenance. Smith and colleagues demonstrated that vulnerable neurons in the brains of individuals with Alzheimer disease have increased mitochondrial degradation products, suggesting a greater turnover of mitochondria by autophagy and/or a reduction of proteolytic turnover and resulting accumulation of products of mitochondrial degradation.23 In mouse models, age-related hearing loss has been associated with an accumulation of oxidative stress induced by reactive oxygen species (ROS); mitochondria are a major source of ROS generation and the site of ROS-induced damage.24 Given our evidence that DIABLOS71L collapses the mitochondrial membrane potential under stress and that DIABLOS71L is associated with progressive hearing loss in the family studied, it is highly likely that the defects caused by DIABLOS71L might ultimately result in chronical mitochondrial dysfunction and thus lead to hair cell degeneration and death. Because hair cells are long-lived terminally differentiated cells, in vivo expression of DIABLOS71L is likely to be less dramatic, and the defects associated with DIABLOS71L will probably be subtle and accumulative and only become pathological over time. This hypothesis is consistent with the late onset and progressive nature of hearing impairment in DFNA64. A mouse model that expresses a mutant allele of DIABLOS71L in a DIABLOwt background will be the next tool in the study of accumulative effects and progressive hearing loss. Furthermore, it remains to be determined which degradation pathway DIABLOS71L activates.

Unveiling new molecular mechanisms of hearing impairment might result in valuable insights into the molecular triggers for hair cell degeneration and provide the basis for genetic diagnosis as well as exciting developments in therapeutic intervention in hearing loss. Work pioneered by Steven McKnight has shown that proneurogenic chemical P7C3 is able to preserve mitochondrial membrane permeability by a yet unknown mechanism.21 Our results raise the possibility of utilizing mitochondria protective compound (such as P7C3) for potential therapeutic benefit to protect hair cell mitochondrial membrane potential and attenuate the progression of hearing loss in DFNA64 individuals. This would represent a new direction for possible intervention in progressive hearing loss among the general deaf population.

Acknowledgments

We sincerely thank Xiaodong Wang for extensive help in invaluable scientific input and manuscript revision, Xue Zhang and Hui Jiang for helpful discussions, and Yueshuai Song and Chunhua Xu for technical assistance with the figure preparation and graphical artwork. These investigations were supported by grants from the National High Technology Research and Development Program of China (863 Program, 2007AA02E466) and the Key Project of National Natural Science Foundation of China (81030017) to H.J.Y., grants from the National Natural Science Foundation of China (30728030) and National Institutes of Health (R01 DC006908) to Z.Y.C., a grant from the Fredrick and Ines Yeatts Inner Ear Hair Cell Regeneration Fellowship to M.P., a grant from the National Institutes of Health (R01 DC05575) to X.Z.L., and a grant from the Chinese National Programs for Fundamental Research and Development (973 Program, 2011CB504506) to H.W.L. We thank all the family members for their participation and support in this study.

Supplemental Data

Document S1. Two Figures and Two Tables
mmc1.pdf (194.5KB, pdf)

Web Resources

The URLs for data presented herein are as follows:

References

  • 1.Liu X.Z., Yan D. Ageing and hearing loss. J. Pathol. 2007;211:188–197. doi: 10.1002/path.2102. [DOI] [PubMed] [Google Scholar]
  • 2.Dror A.A., Avraham K.B. Hearing loss: Mechanisms revealed by genetics and cell biology. Annu. Rev. Genet. 2009;43:411–437. doi: 10.1146/annurev-genet-102108-134135. [DOI] [PubMed] [Google Scholar]
  • 3.Sun X.B., Wei Z.Y., Yu L.M., Wang Q., Liang W. [Prevalence and etiology of people with hearing impairment in China] Zhonghua Liu Xing Bing Xue Za Zhi. 2008;29:643–646. [PubMed] [Google Scholar]
  • 4.Petersen M.B. Non-syndromic autosomal-dominant deafness. Clin. Genet. 2002;62:1–13. doi: 10.1034/j.1399-0004.2002.620101.x. [DOI] [PubMed] [Google Scholar]
  • 5.Resendes B.L., Williamson R.E., Morton C.C. At the speed of sound: gene discovery in the auditory system. Am. J. Hum. Genet. 2001;69:923–935. doi: 10.1086/324122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Steel K.P., Kros C.J. A genetic approach to understanding auditory function. Nat. Genet. 2001;27:143–149. doi: 10.1038/84758. [DOI] [PubMed] [Google Scholar]
  • 7.Lallemend F., Lefebvre P.P., Hans G., Moonen G., Malgrange B. Molecular pathways involved in apoptotic cell death in the injured cochlea: Cues to novel therapeutic strategies. Curr. Pharm. Des. 2005;11:2257–2275. doi: 10.2174/1381612054367346. [DOI] [PubMed] [Google Scholar]
  • 8.Nicotera T.M., Hu B.H., Henderson D. The caspase pathway in noise-induced apoptosis of the chinchilla cochlea. J. Assoc. Res. Otolaryngol. 2003;4:466–477. doi: 10.1007/s10162-002-3038-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Van De Water T.R., Lallemend F., Eshraghi A.A., Ahsan S., He J., Guzman J., Polak M., Malgrange B., Lefebvre P.P., Staecker H., Balkany T.J. Caspases, the enemy within, and their role in oxidative stress-induced apoptosis of inner ear sensory cells. Otol. Neurotol. 2004;25:627–632. doi: 10.1097/00129492-200407000-00035. [DOI] [PubMed] [Google Scholar]
  • 10.Someya S., Xu J., Kondo K., Ding D., Salvi R.J., Yamasoba T., Rabinovitch P.S., Weindruch R., Leeuwenburgh C., Tanokura M., Prolla T.A. Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc. Natl. Acad. Sci. USA. 2009;106:19432–19437. doi: 10.1073/pnas.0908786106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Walsh T., Pierce S.B., Lenz D.R., Brownstein Z., Dagan-Rosenfeld O., Shahin H., Roeb W., McCarthy S., Nord A.S., Gordon C.R. Genomic duplication and overexpression of TJP2/ZO-2 leads to altered expression of apoptosis genes in progressive nonsyndromic hearing loss DFNA51. Am. J. Hum. Genet. 2010;87:101–109. doi: 10.1016/j.ajhg.2010.05.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42. doi: 10.1016/s0092-8674(00)00008-8. [DOI] [PubMed] [Google Scholar]
  • 13.Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43–53. doi: 10.1016/s0092-8674(00)00009-x. [DOI] [PubMed] [Google Scholar]
  • 14.Chai J., Du C., Wu J.W., Kyin S., Wang X., Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 2000;406:855–862. doi: 10.1038/35022514. [DOI] [PubMed] [Google Scholar]
  • 15.Sage C., Huang M., Karimi K., Gutierrez G., Vollrath M.A., Zhang D.S., García-Añoveros J., Hinds P.W., Corwin J.T., Corey D.P., Chen Z.Y. Proliferation of functional hair cells in vivo in the absence of the retinoblastoma protein. Science. 2005;307:1114–1118. doi: 10.1126/science.1106642. [DOI] [PubMed] [Google Scholar]
  • 16.Greene C.C., McMillan P.M., Barker S.E., Kurnool P., Lomax M.I., Burmeister M., Lesperance M.M. DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24. Am. J. Hum. Genet. 2001;68:254–260. doi: 10.1086/316925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Blanton S.H., Liang C.Y., Cai M.W., Pandya A., Du L.L., Landa B., Mummalanni S., Li K.S., Chen Z.Y., Qin X.N. A novel locus for autosomal dominant non-syndromic deafness (DFNA41) maps to chromosome 12q24-qter. J. Med. Genet. 2002;39:567–570. doi: 10.1136/jmg.39.8.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Skvorak A.B., Weng Z., Yee A.J., Robertson N.G., Morton C.C. Human cochlear expressed sequence tags provide insight into cochlear gene expression and identify candidate genes for deafness. Hum. Mol. Genet. 1999;8:439–452. doi: 10.1093/hmg/8.3.439. [DOI] [PubMed] [Google Scholar]
  • 19.Veatch J.R., McMurray M.A., Nelson Z.W., Gottschling D.E. Mitochondrial dysfunction leads to nuclear genome instability via an iron-sulfur cluster defect. Cell. 2009;137:1247–1258. doi: 10.1016/j.cell.2009.04.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Distelmaier F., Koopman W.J., Testa E.R., de Jong A.S., Swarts H.G., Mayatepek E., Smeitink J.A., Willems P.H. Life cell quantification of mitochondrial membrane potential at the single organelle level. Cytometry A. 2008;73:129–138. doi: 10.1002/cyto.a.20503. [DOI] [PubMed] [Google Scholar]
  • 21.Pieper A.A., Xie S., Capota E., Estill S.J., Zhong J., Long J.M., Becker G.L., Huntington P., Goldman S.E., Shen C.H. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010;142:39–51. doi: 10.1016/j.cell.2010.06.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Williams A., Jahreiss L., Sarkar S., Saiki S., Menzies F.M., Ravikumar B., Rubinsztein D.C. Aggregate-prone proteins are cleared from the cytosol by autophagy: Therapeutic implications. Curr. Top. Dev. Biol. 2006;76:89–101. doi: 10.1016/S0070-2153(06)76003-3. [DOI] [PubMed] [Google Scholar]
  • 23.Zhu X., Perry G., Moreira P.I., Aliev G., Cash A.D., Hirai K., Smith M.A. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J. Alzheimers Dis. 2006;9:147–153. doi: 10.3233/jad-2006-9207. [DOI] [PubMed] [Google Scholar]
  • 24.Orrenius S., Gogvadze V., Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu. Rev. Pharmacol. Toxicol. 2007;47:143–183. doi: 10.1146/annurev.pharmtox.47.120505.105122. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Document S1. Two Figures and Two Tables
mmc1.pdf (194.5KB, pdf)

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES